Phase I Trial of Daily Lenalidomide (CC-5013, Revlimid) and Docetaxel Given Every Three Weeks in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2010
At a glance
- Drugs Docetaxel; Lenalidomide
- Indications Solid tumours
- Focus Adverse reactions
- 30 Mar 2010 Actual initiation date changed from Jun 2004 to Jun 2005 and actual patient number (33) as reported by ClinicalTrials.gov.
- 02 Jul 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 15 Oct 2007 Status change from recruiting to in progress.